Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
St. Louis University
Centre Leon Berard
Massachusetts General Hospital
AstraZeneca
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Nebraska
Dren Bio
Lyell Immunopharma, Inc.
Merck Sharp & Dohme LLC
Curis, Inc.
Mayo Clinic
Incyte Corporation
National Institutes of Health Clinical Center (CC)
AVM Biotechnology Inc
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Genmab
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
SecuraBio
The First Affiliated Hospital of Soochow University
Eastern Cooperative Oncology Group
Medical College of Wisconsin
Hoffmann-La Roche
Hoffmann-La Roche
AvenCell Therapeutics, Inc.
Colorado State University
Vironexis Biotherapeutics Inc.
VIVUS LLC
Treeline Biosciences, Inc.
Washington University School of Medicine
Fudan University
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Nurix Therapeutics, Inc.
Center for International Blood and Marrow Transplant Research
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
Mayo Clinic
University of Zurich
M.D. Anderson Cancer Center